{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:56:40Z","timestamp":1761843400688},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.gtc.2005.02.002","type":"journal-article","created":{"date-parts":[[2005,5,6]],"date-time":"2005-05-06T15:34:36Z","timestamp":1115393676000},"page":"319-335","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy of Current Drug Therapies in Irritable Bowel Syndrome: What Works and Does Not Work"],"prefix":"10.1016","volume":"34","author":[{"given":"Philip","family":"Schoenfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2005.02.002_bib1","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0002-9270(02)05657-5","article-title":"Systematic review on the management of irritable bowel syndrome in North America","volume":"97","author":"Brandt","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2005.02.002_bib2","first-page":"69","article-title":"Design of treatment trials for functional gastrointestinal disorders","volume":"45","author":"Van Zanten","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2005.02.002_bib3","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0016-5085(98)70439-1","article-title":"An evidence-based approach to gastroenterology therapy","volume":"114","author":"Schoenfeld","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2005.02.002_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.273.5.408","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2005.02.002_bib5","first-page":"276","article-title":"Irritable colon syndrome treated with an antispasmodic drug","volume":"217","author":"Wheatley","year":"1976","journal-title":"Practitioner"},{"key":"10.1016\/j.gtc.2005.02.002_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM197301042880103","article-title":"A controlled therapeutic study of the irritable bowel syndrome","volume":"288","author":"Greenbaum","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2005.02.002_bib7","first-page":"232","article-title":"Mebeverine in patients with the irritable colon syndrome: double blind study","volume":"77","author":"Tasman-Jones","year":"1973","journal-title":"N Z Med J"},{"key":"10.1016\/j.gtc.2005.02.002_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00004836-198106000-00009","article-title":"Treatment of the irritable bowel syndrome with bentyl (dicyclomine hydrochloride)","volume":"3","author":"Page","year":"1981","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gtc.2005.02.002_bib9","first-page":"377","article-title":"Double blind trial of trimebutine in the irritable bowel syndrome","volume":"73","author":"Fielding","year":"1980","journal-title":"Irish Medical Journal"},{"key":"10.1016\/j.gtc.2005.02.002_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/030006057800600202","article-title":"A trial of trimebutine in spastic colon","volume":"6","author":"Luttecke","year":"1978","journal-title":"J Int Med Res"},{"key":"10.1016\/j.gtc.2005.02.002_bib11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0016-5085(79)90012-X","article-title":"Prifinium bromide in the treatment of the irritable colon syndrome","volume":"77","author":"Piai","year":"1979","journal-title":"Gastroenterol"},{"key":"10.1016\/j.gtc.2005.02.002_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/gut.31.3.355","article-title":"Long-term treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled trial","volume":"31","author":"Dobrilla","year":"1990","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2005.02.002_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000199329","article-title":"Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome","volume":"34","author":"Kruis","year":"1986","journal-title":"Digestion"},{"key":"10.1016\/j.gtc.2005.02.002_bib14","first-page":"967","article-title":"Long-term treatment of irritable bowel syndrome with cimetropium bromide, a new antimuscarinic compound","volume":"41","author":"Piai","year":"1987","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.gtc.2005.02.002_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1185\/03007998009109464","article-title":"A three-part controlled trial of trimebutine in the treatment of irritable colon syndrome","volume":"6","author":"Luttecke","year":"1980","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.gtc.2005.02.002_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.1.6160.376","article-title":"Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk","volume":"10","author":"Ritchie","year":"1979","journal-title":"BMJ"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2005.02.002_bib17","first-page":"60","article-title":"Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy","volume":"23","author":"Baldi","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/j.gtc.2005.02.002_bib18","first-page":"137","article-title":"Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial","volume":"25","author":"Awad","year":"1995","journal-title":"Acta Gastroenterol Latinoam"},{"key":"10.1016\/j.gtc.2005.02.002_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/030006057900700311","article-title":"A clinical trial of trimebutine (Mebutin) in spastic colon","volume":"7","author":"Moshal","year":"1979","journal-title":"J Int Med Res"},{"key":"10.1016\/j.gtc.2005.02.002_bib20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1046\/j.1365-2036.1998.00397.x","article-title":"Otilonium bromide in irritable bowel syndrome: a double blind, placebo-controlled, 1-week study","volume":"12","author":"Battaglia","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib21","first-page":"1262","article-title":"Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome","volume":"83","author":"Centonze","year":"1988","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2005.02.002_bib22","first-page":"541","article-title":"Single drug treatment for irritable colon: rociverine versus trimebutine maleate","volume":"39","author":"Ghidini","year":"1986","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.gtc.2005.02.002_bib23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2036.2001.00937.x","article-title":"Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome","volume":"15","author":"Poynard","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2036.1994.tb00322.x","article-title":"Meta-analysis of smooth muscle relaxants in the treatment of IBS","volume":"8","author":"Poynard","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib25","first-page":"488","article-title":"Behandlung des colon irritabile","volume":"25","author":"Schafer","year":"1990","journal-title":"Fortschr Med"},{"key":"10.1016\/j.gtc.2005.02.002_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0016-5085(90)91292-E","article-title":"Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome","volume":"98","author":"Cook","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2005.02.002_bib27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0140-6736(76)91402-1","article-title":"A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome","volume":"1","author":"Soltoft","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2005.02.002_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(77)90605-5","article-title":"Wheat fibre and irritable bowel syndrome","volume":"2","author":"Manning","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2005.02.002_bib29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/00365528509091653","article-title":"The effect of coarse wheat bran in the irritable bowel syndrome","volume":"20","author":"Arffmann","year":"1985","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2005.02.002_bib30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/gut.28.2.221","article-title":"Is bran efficacious in irritable bowel syndrome? A double-blind, placebo controlled crossover study","volume":"28","author":"Lucey","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2005.02.002_bib31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.1994.tb00323.x","article-title":"Bran supplementation in the treatment of irritable bowel syndrome","volume":"8","author":"Snook","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2036.1993.tb00074.x","article-title":"Calcium polycarbophil compared with placebo in irritable bowel syndrome","volume":"7","author":"Toskes","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.7326\/0003-4819-95-1-53","article-title":"Psyllium therapy for irritable bowel syndrome","volume":"95","author":"Longstreth","year":"1981","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2005.02.002_bib34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.1.6160.376","article-title":"Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk","volume":"1","author":"Ritchie","year":"1979","journal-title":"BMJ"},{"key":"10.1016\/j.gtc.2005.02.002_bib35","first-page":"353","article-title":"Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double-blind crossover study)","volume":"30","author":"Golechha","year":"1982","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.gtc.2005.02.002_bib36","first-page":"253","article-title":"Double-blind trial of ispaghula\/polaxamer in the irritable bowel syndrome","volume":"76","author":"Arthurs","year":"1983","journal-title":"Ir Med J"},{"key":"10.1016\/j.gtc.2005.02.002_bib37","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/gut.28.11.1510","article-title":"Double-blind study of ispaghula in irritable bowel syndrome","volume":"28","author":"Prior","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2005.02.002_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1440-1746.1990.tb01432.x","article-title":"Ispaghula therapy in irritable bowel syndrome: improvement in overall well being is related to reduction in bowel dissatisfaction","volume":"5","author":"Jalihal","year":"1990","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2005.02.002_bib39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.0269-2813.2004.01862.x","article-title":"Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome","volume":"19","author":"Bijkerk","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib40","first-page":"375","article-title":"Intestinal gas production from bacterial fermentation of undigested carbohydrate in IBS","volume":"84","author":"Haderstorfer","year":"1989","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2005.02.002_bib41","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM197509112931103","article-title":"The role of intestinal gas in functional abdominal pain","volume":"293","author":"Lasser","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2005.02.002_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(94)91055-3","article-title":"Bran and IBS: time for reappraisal","volume":"344","author":"Francis","year":"1994","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2005.02.002_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2036.1999.00005.x-i2","article-title":"Review article: clinical evidence to support current therapies of IBS","volume":"13","author":"Camilleri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib44","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/BF02234645","article-title":"Adverse effects of laxatives","volume":"44","author":"Xing","year":"2001","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.gtc.2005.02.002_bib45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0025-6196(12)60796-4","article-title":"Colonic tone and motility in patients with IBS","volume":"67","author":"Vassallo","year":"1992","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.gtc.2005.02.002_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF01296258","article-title":"Role of loperamide and placebo in management of irritable bowel syndrome (IBS)","volume":"29","author":"Cann","year":"1984","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2005.02.002_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528709091004","article-title":"Loperamide treatment of the irritable bowel syndrome","volume":"130","author":"Hovdenak","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.gtc.2005.02.002_bib48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/00365529609006766","article-title":"A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome","volume":"31","author":"Efskind","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2005.02.002_bib49","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1365-2036.2001.00925.x","article-title":"Review article: tegaserod","volume":"15","author":"Camilleri","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib50","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0016-5085(00)70251-4","article-title":"Tegaserod accelerates aro-cecal transit in patients with constipation-predominant irritable bowel syndrome","volume":"118","author":"Prather","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2005.02.002_bib51","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1046\/j.1365-2036.2001.01103.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects","volume":"15","author":"Degen","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib52","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","article-title":"Tegaserod, a 5\u2013HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating, and constipation","volume":"15","author":"Muller-Lissner","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib53","doi-asserted-by":"crossref","first-page":"A1204","DOI":"10.1016\/S0016-5085(00)80649-6","article-title":"Tegaserod has a favorable safety and tolerability profile in patients with constipation-predominant and alternating forms of irritable bowel syndrome","volume":"118","author":"Whorwell","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2005.02.002_bib54","first-page":"A1486","article-title":"Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome: a meta-analysis of randomized controlled trials","volume":"112","author":"Schoenfeld","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2005.02.002_bib55","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","article-title":"A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation","volume":"16","author":"Novick","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib56","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.52.5.671","article-title":"An Asia-Pacific, double-blind, placebo-controlled, randomized study to evaluate the efficacy safety and tolerability of tegaserod in patients with IBS","volume":"522","author":"Kellow","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2005.02.002_bib57","doi-asserted-by":"crossref","first-page":"M1645","DOI":"10.1016\/S0016-5085(03)81972-8","article-title":"Tegaserod is an effective and safe therapy for IBS in a Nordic population","volume":"124","author":"Nyhlin","year":"2003","journal-title":"Gastroenterology"},{"issue":"Suppl 7","key":"10.1016\/j.gtc.2005.02.002_bib58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2036.2004.02182.x","article-title":"The safety profile of tegaserod","volume":"20","author":"Schoenfeld","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib59","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0033-3182(78)70930-8","article-title":"Irritable colon and depression","volume":"19","author":"Heefner","year":"1978","journal-title":"Psychosomatics"},{"key":"10.1016\/j.gtc.2005.02.002_bib60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2190\/WFHG-GR7T-79D6-UQVD","article-title":"Therapeutic usefulness of amitriptyline in spastic colon syndrome","volume":"11","author":"Steinhart","year":"1981","journal-title":"International Journal of Psychologic Medicine"},{"key":"10.1016\/j.gtc.2005.02.002_bib61","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/00365528209181108","article-title":"The effect of trimipramine in patients with irritable bowel syndrome","volume":"17","author":"Myren","year":"1982","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2005.02.002_bib62","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/00365521.1984.12005817","article-title":"A double-blind study of the effect of trimipramine in patients with irritable bowel syndrome","volume":"19","author":"Myren","year":"1984","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2005.02.002_bib63","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01297051","article-title":"Effects of desipramine on irritable bowel syndrome compared with atropine and placebo","volume":"32","author":"Greenbaum","year":"1987","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2005.02.002_bib64","first-page":"243","article-title":"Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients","volume":"33","author":"Vij","year":"1991","journal-title":"Indian J Psychiatry"},{"key":"10.1016\/j.gtc.2005.02.002_bib65","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1440-1746.1998.tb00723.x","article-title":"Symptom relief with amitriptyline in the irritable bowel syndrome","volume":"13","author":"Rajagopalan","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2005.02.002_bib66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0016-5085(03)00669-3","article-title":"Cognitive\u2013behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disease","volume":"125","author":"Drossman","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2005.02.002_bib67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0002-9343(99)00299-5","article-title":"Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis","volume":"108","author":"Jackson","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.gtc.2005.02.002_bib68","first-page":"A630","article-title":"Alosetron slows colonic transit in patients with IBS","volume":"110","author":"Forster","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2005.02.002_bib69","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-2036.1998.00375.x","article-title":"Effect of alosetron on responses to colonic distention in patients with IBS","volume":"12","author":"Delvaux","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib70","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.1999.00610.x","article-title":"Improvement in pain and bowel function in female IBS patients with alosetron, a 5HT3 antagonist","volume":"13","author":"Camilleri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib71","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1046\/j.1365-2036.1999.00678.x","article-title":"Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated IBS patients","volume":"13","author":"Jones","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2005.02.002_bib72","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","article-title":"The efficacy and safety of alosetron in female patients with IBS: a randomized, placebo-controlled study","volume":"355","author":"Camilleri","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2005.02.002_bib73","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/j.1572-0241.2001.04128.x","article-title":"Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant IBS","volume":"96","author":"Lembo","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2005.02.002_bib74","unstructured":"Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis among patients using alosetron: systematic review of clinical trials and postmarketing surveillance data [abstract]. Gastroenterology, in press."},{"key":"10.1016\/j.gtc.2005.02.002_bib75","unstructured":"Chang L, Chey WD, Harris L, et al. Incidence of serious complications of constipation among patients using alosetron: systematic review of clinical trials and postmarketing surveillance data [abstract]. Gastroenterology, in press."}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855305000038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855305000038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T13:40:49Z","timestamp":1625924449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855305000038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0889855305000038"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2005.02.002","relation":{},"ISSN":["0889-8553"],"issn-type":[{"type":"print","value":"0889-8553"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}